SS Innovations (SSII) Stock News

SS Innovations International (NASDAQ:SSII) has completed a crucial human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025, shifting from its previous De Novo pathway strategy.

The company has partnered with RQM+, a MedTech-focused CRO, for the submission process and anticipates potential FDA clearance in H1 2026. Currently, the SSi Mantra has an installed base of 125 units across 6 countries, with over 6,000 surgical procedures completed, including 60 telesurgeries and 310 cardiac procedures.

SS Innovations International (NASDAQ:SSII), a developer of surgical robotic technologies, has appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. Amar succeeds Dr. Vishwa Srivastava, who served as Interim CFO since July 2025 and will continue as CEO of Asia Pacific.

Amar brings over 25 years of global finance leadership experience and has been recognized as one of India's top financial executives by Forbes India, Forbes Asia, and other prestigious organizations. His expertise spans financial accounting, reporting, planning, corporate finance, and both U.S. and Indian GAAP. Prior to joining SSII, Amar provided virtual CFO services and held senior positions at SpiceXpress, Munch Ado India, and other global companies.

SS Innovations (NASDAQ: SSII) has achieved a significant milestone with the world's first pediatric pyeloplasty telesurgery using their SSi Mantra surgical robotic system. The groundbreaking procedure was performed by Dr. Chandra Mohan Vaddi, who operated remotely from Gurugram, India on a 16-month-old patient located 1,000 miles away in Hyderabad.

The company has completed over 50 telesurgeries across multiple categories including pediatric, cardiac, urology, gynecology, oncology, and general surgery, with distances reaching up to 4,000 miles. SS Innovations aims to expand its pediatric robotic surgery capabilities through the development of smaller instrumentation, furthering its mission of democratizing advanced surgical robotic care.

SS Innovations (NASDAQ:SSII) has achieved a significant milestone in telemedicine with the successful completion of the first robotic telesurgery performed from their MantraM mobile robotic telesurgery unit. Dr. Priya Bhave Chittawar conducted a complex hysterectomy remotely from the MantraM bus, connecting to an operating room at HER Health in Bhopal, India, using the company's SSi Mantra surgical robotic system.

The achievement demonstrates the company's progress in making advanced surgical care accessible to underserved communities. The MantraM bus, which began its tour across India in July 2025, serves dual purposes: bringing specialized care to remote locations and providing surgical robotic education to medical professionals. The mobile unit has been visiting hospitals, clinics, conferences, and medical colleges in India's underserved regions.

SS Innovations (NASDAQ:SSII) reported strong Q2 2025 financial results, with record quarterly revenue of $10.0 million, up 121.8% year-over-year. The company's gross margin expanded significantly to 59.1% from 31.9% in Q2 2024, while gross profit surged 311.4% to $5.9 million.

The SSi Mantra surgical robotic system achieved 23 new installations in Q2, a 130% increase from the previous year, bringing the total installed base to 105 systems across seven countries. The company reported 4,657 cumulative surgeries and expects to submit a 510(k) application to the FDA by September 2025. Notable achievements include the world's first robotic cardiac surgery in the Western Hemisphere and breakthrough telesurgery procedures.

The company maintains a strong financial position with zero long-term debt and $11.4 million in cash. SS Innovations successfully uplisted to Nasdaq in April 2025, marking a new phase in its global expansion strategy.

SS Innovations (NASDAQ:SSII) has achieved a groundbreaking milestone by completing the world's first intercontinental robotic cardiac telesurgery. Dr. Sudhir Srivastava, the Company's CEO, successfully performed an atrial septal defect closure on July 19, 2025, operating remotely from IRCAD in Strasbourg, France, to control the SSi Mantra 3 surgical robot located over 4,000 miles away in Indore, India.

The procedure demonstrated flawless precision with imperceptible latency, showcasing the robustness of SSi Mantra 3's telesurgery capabilities. The system has already facilitated 35 telesurgeries, including 10 cardiac procedures, and a total of 5,000+ multi-specialty surgeries without device-related adverse events. SS Innovations is currently the only surgical robotic company with CDSCO approval for both teleproctoring and telesurgery in India.

SS Innovations (NASDAQ:SSII) has achieved a significant milestone by installing over 100 SSi Mantra surgical robotic systems across India and six other countries. The company reported that more than 5,000 surgical procedures have been completed using the system, including 240 cardiac surgeries and 32 telesurgeries, showing substantial growth from the 2,759 total procedures reported as of December 31, 2024.

The company plans to submit a De Novo application to the FDA by July 2025 for multiple indications and is pursuing European Union CE marking certification, expected by late 2025. SS Innovations aims to democratize robotic surgery access by expanding both in existing markets and new geographies.

SS Innovations (NASDAQ:SSII) has achieved a groundbreaking milestone by completing the world's first robotic telesurgery for weight loss using their SSi Mantra 3 surgical robotic system. The surgery was performed by Dr. Mohit Bhandari from a distance of 560 miles, connecting SS Innovations' headquarters in Gurugram to Mohak Bariatric & Robotic Surgery Centre in Indore, India.

Two One-Anastomosis Gastric Bypass (OAGB) procedures were successfully executed with zero perceptible lag and flawless precision. The achievement demonstrates the system's capability to deliver advanced surgical care to remote locations, potentially revolutionizing healthcare accessibility and affordability globally.

SS Innovations International (NASDAQ: SSII) announced the successful completion of the first robotic cardiac surgery in the Americas using their SSi Mantra 3 surgical robotic system. The groundbreaking procedure, an Atrial Septal Defect closure, was performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador on June 8, 2025. The surgery involved repairing a hole between the heart's upper chambers. Dr. Zuniga praised the system's ease of use, precision, and effectiveness, noting faster patient recovery, minimal bleeding, and precise tissue manipulation. Interhospital, the first South American facility to install the SSi Mantra system, has been successfully using it for various complex surgical procedures.